Physician profile
David Barry
NPI 1124559448
$26,220.96
in general payments reported to CMS, 2019-2025
20 companies · $4,844 in 2025
The $4,844 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.08 · 2020: $67.97 · 2021: $284 · 2022: $316 · 2023: $4,187 · 2024: $16K · 2025: $4,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $19K · Travel and Lodging: $3,597 · Food and Beverage: $2,546 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $19,000.00 |
| Travel and Lodging | $3,596.51 |
| Food and Beverage | $2,546.03 |
| Education | $341.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,457.71 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Apollotm |
| Abbott Laboratories | $2,053.83 | 2022-2025 | Triclip, Amplatzer, Navitor |
| W. L. Gore & Associates, INC. | $1,561.63 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder, Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Boston Scientific Corporation | $214.80 | 2024-2025 | Avvigo Guidance System |
| Astrazeneca Pharmaceuticals Lp | $188.63 | 2020-2024 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $106.23 | 2022-2024 | Eliquis, Camzyos |
| Imperative Care, INC | $78.23 | 2025 | Symphony Catheter |
| Cardiovascular Systems INC. | $71.15 | 2022 | |
| Pfizer INC. | $68.08 | 2019 | |
| Corcym INC | $67.42 | 2025 | Perceval |
| Getinge USA Sales, LLC | $67.38 | 2022-2023 | Cardiohelp |
| Edwards Lifesciences Corporation | $48.47 | 2022-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $39.49 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.42 | 2020-2021 | |
| Angiodynamics, INC. | $33.77 | 2025 | Angiovac |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.99 | 2024 | Repatha |
| Abiomed | $31.88 | 2025 | |
| Medtronic Vascular, INC. | $25.07 | 2020 | |
| Biotronik INC. | $20.39 | 2023 | Orsiro Mission |
| Lantheus Medical Imaging, INC. | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.